Document:

Exh_4_4

		
			Exhibit 4.4
		

		
			STOCK PURCHASE AGREEMENT
		

		
			This Stock Purchase Agreement (this “Agreement”) is dated as of January 8, 2018, between Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Incyte Corporation, a Delaware corporation (“Purchaser”).
		

		
			WHEREAS, the Company and Purchaser entered into that certain Target Discovery, Research Collaboration and Option Agreement dated as of the date hereof (the “Collaboration Agreement”); and
		

		
			WHEREAS, in connection with the execution of the Collaboration Agreement, the Company desires to sell to Purchaser, and Purchaser desires to purchase from the Company, shares of Common Stock of the Company in the amount and upon the terms and conditions set forth in this Agreement.
		

		
			NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and Purchaser agree as follows:
		

		
			ARTICLE I.
		

		
			DEFINITIONS
		

		
			1.1       Definitions.  In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:
		

		
			“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.
		

		
			“Board of Directors” means the board of directors of the Company.
		

		
			“Business Day” means any day except Saturday, Sunday and any day on which banking institutions in New York, New York, generally are closed as a result of federal, state or local holiday.
		

		
			“Closing” has the meaning ascribed to such term in Section 2.1.
		

		
			“Collaboration Agreement” has the meaning ascribed to such term in the preamble.
		

		
			“Commission” means the United States Securities and Exchange Commission.
		

		
			“Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.
		

		
			“Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without 
		

		
			
		

		
			

		 

 

		

		
			limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
		

		
			“Company Counsel” means Wilmer Cutler Pickering Hale and Dorr LLP, with offices located at 60 State Street, Boston, MA 02109.
		

		
			“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
		

		
			“Exempt Issuance” means the issuance of (a) shares of Common Stock or options to employees, consultants, officers or directors of the Company pursuant to any stock or option plan or stock purchase plan, as applicable, duly adopted for such purpose and in existence on the date of this Agreement as such plan is constituted on the date of this Agreement, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, unless otherwise agreed to by the non-employee members of the Board of Directors, (b) securities upon the exercise or exchange of or conversion of any Common Stock Equivalents issued and outstanding on the date of this Agreement, provided that such securities have not been amended on or after the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, (c) securities pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, (d) shares of Common Stock in an “at-the-market” offering, and (e) shares of Common Stock or Common Stock Equivalents issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board of Directors.
		

		
			“FCPA” means the Foreign Corrupt Practices Act of 1977, as amended.
		

		
			“FINRA” means the Financial Industry Regulatory Authority.
		

		
			“GAAP” has the meaning ascribed to such term in Section 3.1(g).
		

		
			“Governmental Authority” means any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or country or any supranational organization of which any such country is a member.
		

		
			“Intellectual Property” means patents, patent applications, trademarks, trademark applications, service marks, trade names, trade dress, trade secrets, inventions and discoveries and invention disclosures whether or not patented, copyrights in both published and unpublished works, including without limitation all compilations, data 
		

		
			
		

		
			

		 

		

			2

		

 

		

		
			bases and computer programs, materials and other documentation, licenses, internet domain names and other intellectual property rights and similar rights.
		

		
			“Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.
		

		
			“Lock-Up Period” has the meaning assigned to such term in Section 5.1(a).
		

		
			“Material Adverse Effect” means any (i) material adverse effect on the legality, validity or enforceability of this Agreement, (ii) material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and its Subsidiary, taken as a whole, or (iii) material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under this Agreement.
		

		
			“Order” means any assessment, award, decision, injunction, judgment, order, ruling, verdict or writ entered, issued, made, or rendered by any court, administrative agency, or other Governmental Authority or by any arbitrator.
		

		
			“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
		

		
			“Purchase Price” has the meaning ascribed to such term in Section 2.1.
		

		
			“Registration Statement” means a registration statement on Form S-3 (or any successor form related to secondary offerings) required to be filed hereunder as contemplated by Article IV, including any preliminary prospectus, the prospectus, amendments and supplements to such registration statement, preliminary prospectus or prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement.
		

		
			“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
		

		
			  “SEC Reports” has the meaning ascribed to such term in Section 3.1(g).
		

		
			“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
		

		
			“Shares” has the meaning ascribed to such term in Section 2.1.
		

		
			“Subsidiary” means Syros Securities Corporation, a Massachusetts corporation and the Company’s wholly-owned subsidiary.
		

		
			
		

		
			

		 

		

			3

		

 

		

		
			“Trading Day” means a day on which The NASDAQ Global Select Market is open for trading.
		

		
			“Transfer Agent” means Computershare Ltd, the current transfer agent of the Company, with a mailing address of 250 Royal Street, Canton, MA 02021 and a facsimile number of (781) 575-4647, and any successor transfer agent of the Company.
		

		
			ARTICLE II.
		

		
			 PURCHASE AND SALE
		

		
			2.1       Purchase and Sale of Shares; Closing.  Subject to the terms and conditions of this Agreement, the Company agrees to sell to Purchaser at the Closing, free and clear of all Liens, and Purchaser agrees to purchase from the Company at the Closing, 793,021 shares of Common Stock (the “Shares”) at a price per share of $12.61 for an aggregate purchase price of $9,999,994.81 (the “Purchase Price”).  Subject to the satisfaction or waiver of the conditions set forth in Section 2.4, the Closing shall take place remotely via the exchange of documents and signatures at 10:00 a.m. Eastern Time on the date hereof, or at such other time and location as the Company and Purchaser shall mutually agree (which time and location are designated as the “Closing” and the date thereof as the “Closing Date”).
		

		
			2.2       Delivery and Payment.  At the Closing, subject to the terms and conditions hereof, the Company will deliver the Shares to the Purchaser (and the Company will instruct the Transfer Agent to deliver the Shares to the Purchaser via book entry to the applicable balance account registered in the name of the Purchaser) against payment of the Purchase Price in U.S. dollars by wire transfer of immediately available funds made payable to the order of the Company.
		

		
			2.3       Deliveries at Closing.
		

		
			(a)        Deliveries by the Company.  At the Closing, subject to the terms and conditions of this Agreement, the Company shall deliver or cause to be delivered to the Purchaser the following items:
		

		
			(i)        a legal opinion of Company Counsel dated as of the Closing Date substantially in the form of Exhibit A attached hereto;
		

		
			(ii)       a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, the Shares to the Purchaser, via a book entry position in an account registered in the name of the Purchaser at the Transfer Agent and evidence of Purchaser’s ownership of the Shares from the Transfer Agent in the form of Direct Registration Book Entry Advice;
		

		
			(iii)      a compliance certificate, executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the effect that the conditions specified in Section 2.4(b)(i) and (ii) have been satisfied;
		

		
			
		

		
			

		 

		

			4

		

 

		

		
			(iv)       a certificate of the Company’s Secretary certifying as to (A) the Company’s certificate of incorporation and bylaws, (B) the resolutions of the Board of Directors approving this Agreement and the transactions contemplated hereby, (C) good standing certificates with respect to the Company from the applicable authorities in the State of Delaware and each state in which the Company is qualified to do business as a foreign corporation, dated a recent date before the Closing, and (D) the incumbency and specimen signature of any officer of the Company executing this Agreement on behalf of the Company; and
		

		
			(v)        all such other documents, certificates and instruments as the Purchaser may reasonably request in order to give effect to the transactions contemplated hereby.
		

		
			(b)        Deliveries by the Purchaser.  At the Closing, the Purchaser shall deliver or cause to be delivered to the Company the Purchase Price, by wire transfer of immediately available funds to one or more accounts designated by the Company no later than two (2) Business Days prior to the Closing Date.
		

		
			2.4       Closing Conditions.
		

		
			(a)        The obligation of the Company to sell the Shares to Purchaser at the Closing is subject to the following conditions being met or waived in writing by the Company:
		

		
			(i)         the representations and warranties of Purchaser contained in Section 3.2 shall be true and correct as of the date hereof (unless specifically made as of another date, in which case as of such other date, and after giving effect to any materiality or other qualifiers contained therein);
		

		
			(ii)       Purchaser shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by Purchaser on or before the Closing;
		

		
			(iii)      Purchaser shall have executed and delivered the Collaboration Agreement; and
		

		
			(iv)       Purchaser shall have delivered the Purchase Price.
		

		
			(b)        The obligation of Purchaser to purchase the Shares at the Closing is subject to the following conditions being met or waived in writing by Purchaser:
		

		
			(i)         the representations and warranties of the Company contained in Section 3.1 shall be true and correct as of the date hereof (unless specifically made as of another date, in which case as of such other date, and after giving effect to any materiality or other qualifiers contained therein);
		

		
			(ii)       the Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement 
		

		
			
		

		
			

		 

		

			5

		

 

		

		
			that are required to be performed or complied with by the Company on or before the Closing;
		

		
			(iii)      the Company shall have executed and delivered the Collaboration Agreement;
		

		
			(iv)       the Company shall have delivered or caused to be delivered to the Purchaser the items set forth in Section 2.3(a) of this Agreement;
		

		
			(v)        the sale and issuance of the Shares shall be legally permitted by all laws to which the Purchaser and the Company are subject;
		

		
			(vi)       no Order shall be in effect preventing the consummation of the transactions contemplated by this Agreement or the Collaboration Agreement;
		

		
			(vii)     all consents necessary or appropriate for consummation of the transactions contemplated by this Agreement shall have been obtained;
		

		
			(viii)    no Material Adverse Effect shall have occurred and be continuing; and
		

		
			(ix)       the Company’s Common Stock shall continue to be listed on The NASDAQ Global Select Market.
		

		
			ARTICLE III.
		

		
			 REPRESENTATIONS AND WARRANTIES
		

		
			3.1       Representations and Warranties of the Company.  The Company hereby represents and warrants to Purchaser as of the date hereof (unless specifically made as of another date, in which case as of such other date) as follows:
		

		
			(a)        Capitalization.  The capitalization of the Company as of September 30, 2017 is as set forth in the SEC Reports.  The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of stock options under the Company’s stock incentive plans and the issuance of shares of Common Stock pursuant to the Company’s at-the-market sales agreement. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by this Agreement.  Except as disclosed on Schedule 3.1(a) and as a result of the purchase and sale of the Shares, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents.  The issuance and sale of the Shares will not obligate the Company to issue shares of Common Stock or other securities to any Person and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any 
		

		
			
		

		
			

		 

		

			6

		

 

		

		
			of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.  No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Shares.  Except as disclosed on Schedule 3.1(a), there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.  The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to the Company’s knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
		

		
			(b)        Litigation.  There are no actions, suits, proceedings or, to the knowledge of the Company, any investigations, pending or currently threatened against the Company or its Subsidiary that question the validity of this Agreement or the issuance of the Shares contemplated hereby or would, if there were an unfavorable decision, have or could reasonably be expected to result in a Material Adverse Effect.  As of the date hereof, there is no material action, suit, or proceeding pending or, to the knowledge of the Company, currently threatened against the Company or its Subsidiary.  As of the date hereof, there are no material outstanding consents, orders, decrees or judgments of any governmental entity naming the Company or its Subsidiary.  Neither the Company, its Subsidiary nor, to the knowledge of the Company, any director or officer thereof, is or has been the subject of any action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.  There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company, its Subsidiary or any current or former director or officer of the Company or its Subsidiary.  The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities Act.
		

		
			(c)        Organization and Good Standing.  The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and its Subsidiary is a corporation duly organized, validly existing and in good standing under the laws of the Commonwealth of Massachusetts.  Each of the Company and its Subsidiary has all requisite corporate power and authority to own, lease and operate its properties and carry on its business as now conducted and as proposed to be conducted as described in the SEC Reports.  Each of the Company and the Subsidiary is duly qualified and is in good standing as a foreign corporation in each jurisdiction in which the properties owned, leased or operated, or the business conducted, by it requires such qualification except where the failure to be so qualified or in good standing, individually or in the aggregate, would not have a Material Adverse Effect.
		

		
			(d)        Authorization.  All corporate actions on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and 
		

		
			
		

		
			

		 

		

			7

		

 

		

		
			delivery of this Agreement and for the issuance of the Shares have been taken.  The Company has the requisite corporate power to enter into this Agreement and to carry out and perform its obligations hereunder.  This Agreement has been duly authorized, executed and delivered by the Company and, upon due execution and delivery by Purchaser, will be a valid and binding agreement of the Company, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or by equitable principles.
		

		
			(e)        Subsidiary.  The Company owns, directly or indirectly, all of the capital stock or other equity interests of the Subsidiary free and clear of any Liens.  All of the issued and outstanding shares of capital stock of the Subsidiary are validly issued, fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.  Other than the Subsidiary, the Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity, and the Subsidiary is the only entity the Company is required to disclose pursuant to Item 601(b)(21) of Regulation S-K in an exhibit to its Annual Report on Form 10-K.  Except as disclosed in the SEC Reports, the Company is not a participant in any material joint venture, partnership or similar arrangement.
		

		
			(f)        No Conflict With Other Instruments.  Neither the execution, delivery nor performance of this Agreement, nor the issuance of the Shares will result in (i) any violation of, be in conflict with, cause any acceleration or any increased payments under, or constitute a default under, with or without the passage of time or the giving of notice: (a) any provision of the Company’s certificate of incorporation or bylaws; (b) any provision of any judgment, decree or order to which the Company or its Subsidiary is a party or by which it is bound; (c) any law, rule or regulation applicable to the Company or its Subsidiary; or (d) any note, mortgage, material contract, material agreement, material license, waiver, exemption, order or permit; or (ii) the creation or imposition of any lien, encumbrance, claim, security interest or restriction whatsoever upon any of the material properties or assets of the Company or its Subsidiary or an acceleration of indebtedness pursuant to any obligation, agreement or condition contained in any material bond, debenture, note or any other evidence of indebtedness or any material indenture, mortgage, deed of trust or any other agreement or instrument to which the Company or its Subsidiary is a party or by which it is bound or to which any of the material property or assets of the Company or its Subsidiary is subject.
		

		
			(g)        Disclosure Documents.  Since July 6, 2016, the Company has filed, on a timely basis or has received a valid extension as of such time of filing and has thereafter made such filings prior to the expiration of any such extension, all reports, schedules, forms, statements and other documents required to be filed by the Company with the Commission under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”), and the Company has paid all fees and assessments due and payable in connection with the SEC Reports.  As of their respective dates, the SEC Reports complied in all material respects with all statutes and applicable rules and regulations of 
		

		
			
		

		
			

		 

		

			8

		

 

		

		
			the Commission, including the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  Other than the transactions that are the subject of this Agreement and the Collaboration Agreement, no material fact or circumstance exists that would be required to be disclosed in a current report on Form 8-K or in a registration statement filed under the Securities Act, were such a registration statement filed on the date hereof, which has not been disclosed in an SEC Report.  The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.  Such financial statements (i) have been prepared in accordance with United States generally accepted accounting principles (“GAAP”), applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP and (ii) fairly present in all material respects the financial position of the Company and its consolidated Subsidiary as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
		

		
			(h)        Absence of Certain Events and Changes.  Except as otherwise disclosed in the SEC Reports, since the date of the Company’s Quarterly Report on Form 10-Q for the quarter ended on September 30, 2017: (i) each of the Company and its Subsidiary has conducted its business in the ordinary course consistent with past practice, (ii) there has not been any event, change or development which, individually or in the aggregate, has had or could reasonably be expected to have a Material Adverse Effect, (iii) neither the Company nor its Subsidiary has incurred any material liabilities (absolute or accrued, contingent or otherwise) other than expenses incurred in the ordinary course of business consistent with past practice, (iv) neither the Company nor its Subsidiary has altered its method of accounting in any material respect, and (v) the Company has not declared or made any dividend or distribution of cash or other property to its shareholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock.
		

		
			(i)         Intellectual Property.  Except as otherwise disclosed by the Company in writing to Purchaser, the Company owns, or has the right pursuant to a valid, written license agreement to use and exploit, all Intellectual Property used in or necessary for the conduct of the business of the Company and that is material to the business of the Company as conducted as of the date hereof (the “Company Intellectual Property”).  The Subsidiary does not own or have the right to use any Intellectual Property, other than shrink wrap licenses for business software used in the ordinary course of the business presently conducted by the Subsidiary.  The Company Intellectual Property that is owned by the Company is owned free from any Liens (other than any Liens set forth in any license agreement relating to such Company Intellectual Property), and all of the Company’s material licenses are in full force and effect in accordance with their terms, are free of any Liens and neither the Company nor, to the Company’s knowledge, any 
		

		
			
		

		
			

		 

		

			9

		

 

		

		
			other party thereto is in material breach of any such material license, and no event has occurred that with notice or lapse of time or both would constitute such a breach or default thereunder or would result in the termination thereof or would cause or permit the acceleration or other change of any right or obligation or the loss of any benefit thereunder by the Company, except for such failures to be in full force and effect, such Liens and such material breaches that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.  To the knowledge of the Company, (i) all issued patents and registered trademarks that are Company Intellectual Property and that are owned by the Company are valid and enforceable and are currently in compliance with formal legal requirements (including without limitation, as applicable, payment of filing, examination and maintenance fees, proofs of work or use, timely post registration filing of affidavits of use and incontestability and renewal applications), and (ii) there is no existing infringement or misappropriation by another Person of any of the Company Intellectual Property that has had or could reasonably be expected to have a Material Adverse Effect.  Except as disclosed in the SEC Reports, since July 1, 2016, no claims have been asserted by a third party in writing and there are no proceedings pending (of which the Company has received notice or otherwise has knowledge) or, to the knowledge of the Company, threatened (a) alleging that the conduct of the business of the Company has infringed or misappropriated any Intellectual Property rights of such third party, or (b) challenging the validity or effectiveness of any Company Intellectual Property, and, to the Company’s knowledge, there is no valid basis for any such claim.  No loss or early expiration of any of the Company Intellectual Property is pending, or, to the Company’s knowledge, threatened.  The Company has taken reasonable steps in accordance with standard industry practices to protect its rights in the Company Intellectual Property and to maintain the confidentiality of all information used in connection with its business that constitutes or constituted a trade secret of the Company.
		

		
			(j)         Compliance.  Each of the Company and its Subsidiary has all material permits, licenses, franchises, authorizations, orders and approvals of (collectively, “Permits”), and has made all filings, applications and registrations with, Governmental Authorities that are required in order to permit the Company or its Subsidiary, as applicable, to own or lease its properties and assets and to carry on its business as presently conducted.  Neither the sale of the Shares hereunder nor the performance of the Company’s other obligations under this Agreement will result in the suspension, revocation, impairment, forfeiture or nonrenewal of any Permit applicable to the Company or its Subsidiary, their respective businesses or operations or any of their respective assets or properties.  Each of the Company and its Subsidiary has complied and is in compliance in all material respects with all Permits, statutes, laws, regulations, rules, judgments, orders and decrees of all Governmental Authorities applicable to it that relate to its business, including but not limited to compliance with the FCPA and any applicable similar laws in foreign jurisdictions in which the Company or its Subsidiary is currently, or has previously, conducted its business.  Neither the Company nor its Subsidiary has received any notice alleging noncompliance, and, to the knowledge of the Company, neither the Company nor its Subsidiary is under investigation with respect to, or threatened to be charged with, any material violation of any applicable statutes, laws, regulations, rules, judgments, orders or decrees of any governmental entities.  Neither the Company nor its Subsidiary has received any notice of proceedings relating to the 
		

		
			
		

		
			

		 

		

			10

		

 

		

		
			revocation or modification of any Permit. No Permit is subject to termination as a result of the execution of this Agreement or consummation of the transactions contemplated hereby.  Except as disclosed in the SEC Reports, since July 1, 2016, neither the Company nor its Subsidiary has entered into or been subject to any judgment, consent decree, compliance order or administrative order with respect to any aspect of the business, affairs, properties or assets of the Company or its Subsidiary or received any formal or informal complaint or claim from any regulatory agency with respect to any aspect of the business, affairs, properties or assets of the Company or its Subsidiary.
		

		
			(k)        Clinical Data and Regulatory Compliance.  To the Company’s knowledge, (i) the preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the SEC Reports were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies pursuant to, where applicable, accepted professional scientific standards; (ii) each description of the results of such studies in the SEC Reports is accurate and complete in all material respects and fairly presents the data derived from such studies; (iii) the Company has no knowledge of any other studies not disclosed in the SEC Reports the results of which are inconsistent in any material respect with, or otherwise call into question, the results described or referred to in the SEC Reports; (iv) the Company has made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or comparable federal, state, local or foreign Governmental Authorities (collectively, the “Regulatory Agencies”) in order to permit the Company to carry on its business as now conducted and as proposed to be conducted, except where any failures to make or obtain the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) except as described in the SEC Reports, the Company has not received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the SEC Reports; and (vi) the Company has operated and currently is in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies governing its business.
		

		
			(l)         Clinical Trials.  Each Investigational New Drug (“IND”) application submitted to the FDA by the Company and, to the knowledge of the Company, each IND submitted by a third party in relation to the Company’s product candidates, and related documents and information, has been filed, approved and maintained in compliance in all material respects with applicable statutes, rules, regulations or orders administered or promulgated by the FDA or other Regulatory Agency, and all pre-clinical and clinical studies undertaken to support approval of products for commercialization have been conducted in compliance with all applicable current Good Laboratory Practices and Good Clinical Practices in all material respects.  No filing or submission to the FDA or any other Regulatory Agency by the Company and, to the knowledge of the Company, no filing or submission to the FDA or any other Regulatory Agency by a third party that is intended to be the basis for any approval for one of the Company’s product candidates, contains any material omission or material false information.
		

		
			
		

		
			

		 

		

			11

		

 

		

		
			(m)       Valid Issuance of Shares.  The Shares are duly authorized and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens (other than as arising pursuant to this Agreement, as a result of any action by the Purchaser or under federal or state securities laws), and, based in part on the representations of Purchaser in Section 3.2 of this Agreement, will be issued in compliance with all applicable federal and state securities laws.  Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Shares by any form of general solicitation or general advertising. The Company has offered the Shares for sale only to Purchaser.
		

		
			(n)        Governmental Consents.  No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any Governmental Authority on the part of the Company is required in connection with the Company’s execution, delivery and performance of this Agreement and the consummation of the transactions contemplated by this Agreement, except such as have been obtained or made by the Company and are in full force and effect and except for notices required or permitted to be filed with certain state and federal securities commissions, which notices will be filed on a timely basis.
		

		
			(o)        No Brokers.  No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based on arrangements made by the Company.
		

		
			(p)        No Undisclosed Liabilities.  Neither the Company nor its Subsidiary has any liabilities (absolute or accrued, contingent or otherwise), except for (i) liabilities reflected or reserved against in consolidated financial statements of the Company and its Subsidiary (or otherwise disclosed in the accompanying footnotes) included in the SEC Reports filed with the Commission prior to the date of this Agreement, (ii) liabilities incurred in the ordinary course of business or otherwise disclosed in SEC Reports subsequent to the period covered by the Company’s Quarterly Report on Form 10-Q for the quarter ended on September 30, 2017 and (iii) liabilities that have not been and would not reasonably be expected, individually or in the aggregate, to be material.
		

		
			(q)        Internal Controls.  The Company has implemented and maintains a system of internal control over financial reporting (as required by Rule 13a-15(a) under the Exchange Act) that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes, and, to the knowledge of the Company, such system of internal control over financial reporting is effective. For purposes of this Section 3.1(q), “knowledge of the Company” means the actual knowledge of the Principal Executive Officer and Principal Financial Officer of the Company as of the date hereof. The Company has implemented and maintains disclosure controls and procedures (as required by Rule 13a-15(a) of the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the timeframes specified by the Commission’s rules and forms (and such disclosure controls and procedures are effective), and has disclosed, based on its most recent evaluation of its system of internal 
		

		
			
		

		
			

		 

		

			12

		

 

		

		
			control over financial reporting prior to the date of this Agreement, to the audit committee of the Board of Directors, (i) any significant deficiencies and material weaknesses known to it in the design or operation of its internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that would reasonably be expected to adversely affect the Company’s ability to record, process, summarize and report financial information and (ii) any fraud known to it, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.
		

		
			(r)        Company Not An “Investment Company.”  The Company has been advised of the rules and requirements under the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Company is not, and immediately after receipt of payment for the Shares will not be, an “investment company” or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act.
		

		
			(s)        Solvency.  Neither the Company nor its Subsidiary has: (i) made a general assignment for the benefit of creditors; (ii) filed any voluntary petition in bankruptcy or suffered the filing of any involuntary petition by its creditors; (iii) suffered the appointment of a receiver to take possession of all, or substantially all, of its assets; (iv) suffered the attachment or other judicial seizure of all, or substantially all, of its assets; (v) admitted in writing its inability to pay its debts as they come due; or (vi) made an offer of settlement, extension or composition to its creditors generally.
		

		
			(t)         No Integrated Offering.  Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Shares to be integrated with prior offerings by the Company for purposes of the Securities Act or any applicable shareholder approval provisions, including, without limitation, under the rules and regulations of The NASDAQ Global Select Market.
		

		
			(u)        Whistleblowers.  To the knowledge of the Company, as of the date hereof, no employee of the Company or its Subsidiary has provided since July 1, 2016 or is providing information to any law enforcement agency regarding the violation of any applicable law of the type described in Section 806 of the Sarbanes-Oxley Act by the Company or its Subsidiary.  Neither the Company nor its Subsidiary have discharged, demoted or suspended an employee of the Company or its Subsidiary in the terms and conditions of employment because of any lawful act of such employee described in Section 806 of the Sarbanes-Oxley Act.
		

		
			(v)        Foreign Corrupt Practices.  Neither the Company, its Subsidiary nor, to the knowledge of the Company, any agent or other Person acting on behalf of the Company or its Subsidiary has (i) directly or indirectly, used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity; (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or 
		

		
			
		

		
			

		 

		

			13

		

 

		

		
			campaigns from corporate funds; (iii) failed to disclose fully any contribution made by the Company or its Subsidiary (or made by any Person acting on behalf of the Company or its Subsidiary of which the Company is aware) which is in material violation of law; or (iv) violated in any material respect any provision of the FCPA or any non-U.S. anti-bribery law applicable to the Company or its Subsidiary.
		

		
			(w)       Regulation M Compliance.  The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares; (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of any of the Shares; or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, in each case in violation of Regulation M or to the extent otherwise unlawful.
		

		
			(x)        Office of Foreign Assets Control.  Neither the Company, its Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department.
		

		
			3.2       Representations and Warranties of Purchaser.  Purchaser hereby represents and warrants to the Company as of the date hereof (unless specifically made as of another date, in which case as of such other date) as follows:
		

		
			(a)        Legal Power.  Purchaser has the requisite corporate power to enter into this Agreement and to carry out and perform its obligations hereunder.
		

		
			(b)        Due Execution.  This Agreement has been duly authorized, executed and delivered by Purchaser, and, upon due execution and delivery by the Company, will constitute a valid and legally binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or by equitable principles.
		

		
			(c)        Investment Representations.  In connection with the offer, purchase and sale of the Shares, Purchaser makes the following representations:
		

		
			(i)         Purchaser is acquiring the Shares for its own account for the purpose of investment and not with a view to or for sale in connection with any distribution thereof, and has no present intention to effect, or any present or contemplated plan, agreement, undertaking, arrangement, obligation, indebtedness, or commitment providing for, any distribution of the Shares.
		

		
			(ii)        Purchaser has carefully reviewed the representations concerning the Company contained in this Agreement and has made detailed inquiry concerning the Company, its business and its personnel.
		

		
			
		

		
			

		 

		

			14

		

 

		

		
			(iii)      Purchaser understands that the Shares have not been registered under the Securities Act or any applicable state securities laws and, consequently, Purchaser may have to bear the risk of owning the Shares for an indefinite period of time because the Shares may not be transferred unless (x) the resale of the Shares is registered pursuant to an effective registration statement under the Securities Act in accordance with the terms and conditions set forth in Section 4.1 hereof; (y) Purchaser has delivered to the Company an opinion of counsel (in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration; or (z) the Shares are sold or transferred pursuant to Rule 144.
		

		
			(iv)       Purchaser has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Shares to be purchased hereunder.
		

		
			(v)        Purchaser is an “accredited investor” as defined in Rule 501(a) of the rules and regulations promulgated under the Securities Act.
		

		
			(d)        Certain Fees.  No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based on arrangements made by Purchaser.
		

		
			(e)        Legends.  In connection with the issuance and sale of the Shares, Purchaser understands that each of the Shares, whether certificated or in book-entry form, will be endorsed with the following legend:
		

		
			“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.  THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.”
		

		
			The Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties contained in the Collaboration Agreement or any other document or instrument executed and/or delivered in connection with this Agreement or the Collaboration Agreement or the consummation of the transactions contemplated hereby.
		

		
			
		

		
			

		 

		

			15

		

 

		

		
			ARTICLE IV.
		

		
			 REGISTRATION RIGHTS
		

		
			4.1       Registration of the Shares.  The Company shall file with the Commission, on or before the date that is twenty (20) days after the Closing Date or, in the case of securities sold to the Purchaser pursuant to the participation rights set forth in Section 5.8 hereof, thirty (30) days after the delivery of such securities to the Purchaser, a Registration Statement covering the resale to the public by Purchaser of the Shares or securities sold to the Purchaser pursuant to Section 5.8 hereof.  (For purposes of this Article IV, the term “Shares” shall also refer to securities sold to the Purchaser pursuant to Section 5.8.)  The Company shall use commercially reasonable efforts to cause the Registration Statement covering the Shares to be declared effective by the Commission by March 30, 2018 or, in the case of securities sold to the Purchaser pursuant to the participation rights set forth in Section 5.8 hereof, within ninety (90) days after the delivery of such securities to the Purchaser.  The Company shall cause such Registration Statement to remain effective under the Securities Act until all Shares covered by such Registration Statement have been sold or may be sold without volume restrictions pursuant to Rule 144.  The Company shall promptly notify Purchaser of the effectiveness of such Registration Statement after the Company confirms effectiveness with the Commission.  The Company hereby covenants and agrees to use reasonable commercial efforts to maintain its eligibility to make filings with the Commission on Form S-3 until one or more Registration Statements covering the resale of all of the Shares shall have been filed with, and declared effective by, the Commission pursuant to the terms and conditions of this Agreement.
		

		
			4.2       Registration Default.  In relation to the Shares sold under this Agreement, in the event that the Registration Statement has not been declared effective by March 30, 2018 (it being acknowledged and agreed that there shall be no cure period for any such breach), the Company shall pay to the Purchaser a fee of one percent (1%) of the Purchase Price (i) within seven (7) days after March 30, 2018 and (ii) for every thirty (30) day period thereafter that the Registration Statement has not been declared Effective (with the initial such thirty (30) day period commencing on March 30, 2018), up to a maximum of six percent (6%) of the Purchase Price for any such fees due to the Purchaser under (i) and (ii), in the aggregate; provided, however, that the Company shall not be obligated to pay any such liquidated damages if: (a) the Company has complied with all obligations of the Company set forth in Section 4.1 and has filed responses to any comments from the Commission related to the Registration Statement within ten (10) Business Days of receiving such comments; (b) the Shares that would otherwise be covered by the Registration Statement may be sold without the requirement to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144 under the Securities Act; or (c) the Company is unable to fulfill its registration obligations as a result of rules, regulations, positions or releases issued or actions taken by the Commission pursuant to its authority with respect to Rule 415, and the Company registers at such time the maximum number of shares of Common Stock permissible upon consultation with the staff of the Commission; provided, further, that if the Purchaser fails to provide the Company with any information that is required to be provided in such Registration Statement with respect to the Purchaser, then the commencement of the first thirty (30) day period described above shall be extended until two (2) Business Days following the date of receipt by the Company of such required information.  For the avoidance of doubt, this Section 4.2 shall not apply to any securities sold to the Purchaser pursuant to the participation rights set forth in Section 5.8 hereof.
		

		
			
		

		
			

		 

		

			16

		

 

		

		
			4.3       Registration Covenant.  Purchaser covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with sales of the Shares pursuant to a Registration Statement.  The Company shall comply in all material respects with all applicable rules and regulations of the Commission applicable to the filing of a Registration Statement.
		

		
			4.4       Registration Procedures.
		

		
			(a)        In connection with the filing by the Company of a Registration Statement covering the Shares, the Company shall furnish to Purchaser (i) a copy of the prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act and (ii) such other documents as Purchaser may reasonably request, in order to facilitate the public sale or other disposition of the Shares.
		

		
			(b)        The Company shall use commercially reasonable efforts to register or qualify the Shares covered by a Registration Statement under the securities laws of each state of the United States as Purchaser shall reasonably request; provided, however, that the Company shall not be required in connection with this subsection (b) to qualify as a foreign corporation or execute a general consent to service of process in any jurisdiction.
		

		
			(c)        If the Company has delivered preliminary or final prospectuses to Purchaser and after having done so the prospectus is amended or supplemented to comply with the requirements of the Securities Act, the Company shall promptly notify Purchaser and, if requested by the Company, Purchaser shall immediately cease making offers or sales of the Shares covered by a Registration Statement and return all prospectuses to the Company.  The Company shall promptly provide Purchaser with revised or supplemented prospectuses and, following receipt of the revised or supplemented prospectuses, Purchaser shall be free to resume making offers and sales of the Shares under such Registration Statement.
		

		
			(d)        The Company shall be entitled to include in a Registration Statement the shares of Common Stock held by other shareholders of the Company, provided such other shares of Common Stock are excluded first from such Registration Statement in order to comply with any applicable laws or request from any Governmental Authority or The NASDAQ Global Select Market, or in the case of an underwritten offering, in order to comply with a cutback request of any underwriter.
		

		
			(e)        The Company shall pay all expenses incurred in connection with the preparation and filing of such Registration Statement pursuant to this Article IV, including all registration and filing fees and printer, legal and accounting fees related thereto but excluding (i) any brokerage fees, selling commissions or underwriting discounts incurred by Purchaser in connection with sales under any Registration Statement covering the Shares and (ii) the fees and expenses of counsel retained by Purchaser.
		

		
			(f)        The Company shall use commercially reasonable efforts to avoid the issuance of any order suspending the effectiveness of a Registration Statement, or any 
		

		
			
		

		
			

		 

		

			17

		

 

		

		
			suspension of the qualifications (or exemption from qualification) of any of the Shares covered by a Registration Statement for sale in any jurisdiction.  The Company shall advise Purchaser promptly after it shall receive notice of any stop order or issuance of any order by the Commission delaying or suspending the effectiveness of a Registration Statement covering the Shares or of the initiation of any proceeding for that purpose, and it will promptly use commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal at the earliest possible moment if such stop order should be issued.
		

		
			4.5       Registration Confidentiality.  Purchaser agrees to treat as confidential (unless otherwise publicly disclosed by the Company or a third party not to the knowledge of Purchaser in breach of an agreement of confidentiality with the Company) any written notice from the Company regarding the Company’s plans to file a Registration Statement and shall not disclose such information to any other person, or use such information, except as is necessary to exercise its rights under this Agreement.
		

		
			4.6       Indemnification.
		

		
			(a)        The Company agrees to indemnify and hold harmless Purchaser and each other person, if any, who controls Purchaser within the meaning of the Securities Act or Exchange Act from and against any losses, claims, damages or liabilities to which Purchaser or controlling person may become subject (under the Securities Act, the Exchange Act, state securities or “Blue Sky” laws or otherwise) insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement covering the Shares or in any preliminary prospectus or final prospectus contained in such Registration Statement, or any amendment or supplement to such Registration Statement, or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, or (ii) any violation by the Company of the Securities Act or the Exchange Act, or any rule or regulation promulgated under the Securities Act or the Exchange Act, applicable to the Company and relating to action or inaction required of the Company in connection with such registration.  The Company will reimburse Purchaser or controlling person for any reasonable legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim, or preparing to defend any such action, proceeding or claim; provided, however, that the Company shall not be liable in any such case to the extent that such loss, claim, damage or liability arises out of, or is based upon, an untrue statement made in such Registration Statement, preliminary prospectus or prospectus, or any amendment or supplement in reliance upon and in conformity with written information furnished to the Company by or on behalf of Purchaser or controlling person specifically for use in the preparation thereof.
		

		
			(b)        Purchaser agrees to indemnify and hold harmless the Company and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act, each officer of the Company who signs the Registration Statement and each director of the Company, from and against any losses, claims, damages or liabilities 
		

		
			
		

		
			

		 

		

			18

		

 

		

		
			to which the Company or any officer, director or controlling person may become subject (under the Securities Act, the Exchange Act, state securities or “Blue Sky” laws or otherwise), insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon any untrue statement of a material fact contained in any Registration Statement covering the Shares or in any preliminary prospectus, final prospectus contained in such Registration Statement, or any amendment or supplement to such Registration Statement or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, if such untrue statement or omission was made in reliance upon and in conformity with written information furnished by or on behalf of Purchaser specifically for use in preparation of the Registration Statement, prospectus, amendment or supplement and Purchaser will reimburse the Company, or such officer, director or controlling person, as the case may be, for any legal or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim; provided, however, that Purchaser’s obligation to indemnify the Company shall be limited to the Purchase Price.
		

		
			(c)        Promptly after receipt by any indemnified person of a notice of a claim or the beginning of any action in respect of which indemnity is to be sought against an indemnifying person pursuant to this Section 4.6, such indemnified person shall notify the indemnifying person in writing of such claim or of the commencement of such action, but the omission to so notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party under this Section 4.6 (except to the extent that such omission materially and adversely affects the indemnifying party’s ability to defend such action).  Subject to the provisions hereinafter stated, in case any such action shall be brought against an indemnified person, the indemnifying person shall be entitled to participate therein, and, to the extent that it shall elect by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, shall be entitled to assume the defense thereof, with counsel reasonably satisfactory to such indemnified person.  After notice from the indemnifying person to such indemnified person of its election to assume the defense thereof, such indemnifying person shall not be liable to such indemnified person for any legal expenses subsequently incurred by such indemnified person in connection with the defense thereof; provided, however, that if there exists or shall exist a conflict of interest that would make it inappropriate, in the opinion of counsel to the indemnified person, for the same counsel to represent both the indemnified person and such indemnifying person or any Affiliate or associate thereof, the indemnified person shall be entitled to retain its own counsel at the expense of such indemnifying person; and provided, further, that no indemnifying person shall be responsible for the fees and expenses of more than one separate counsel (together with appropriate local counsel) for all indemnified parties.  In no event shall any indemnifying person be liable in respect of any amounts paid in settlement of any action unless the indemnifying person shall have approved the terms of such settlement; provided, however, that such consent shall not be unreasonably withheld.  No indemnifying person shall, without the prior written consent of the indemnified person, effect any settlement of any pending or threatened proceeding in respect of which any indemnified person is or could have been a party and indemnification could have been sought hereunder by such indemnified person, unless such settlement includes an 
		

		
			
		

		
			

		 

		

			19

		

 

		

		
			unconditional release of such indemnified person from all liability on claims that are the subject matter of such proceeding.
		

		
			(d)        If the indemnification provided for in this Section 4.6 is unavailable to or insufficient to hold harmless an indemnified party under subsection (a) or (b) above in respect of any losses, claims, damages or liabilities (or actions or proceedings in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of the Company on the one hand and Purchaser on the other hand, in connection with the statements or omissions or other matters which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations.  The relative fault shall be determined by reference to, among other things, in the case of an untrue statement, whether the untrue statement relates to information supplied by the Company on the one hand or Purchaser on the other hand and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement.  The Company and Purchaser agree that it would not be just and equitable if contribution pursuant to this subsection (d) were determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations referred to above in this subsection (d).  The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.  Notwithstanding the provisions of this subsection (d), Purchaser shall not be required to contribute any amount in excess of the amount by which the net amount received by Purchaser from the sale of the Shares to which such loss relates exceeds the amount of any damages which Purchaser has otherwise been required to pay by reason of such untrue statement.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
		

		
			(e)        The rights and obligations of the Company and Purchaser under this Section 4.6 shall survive the termination of this Agreement.
		

		
			ARTICLE V.
		

		
			COVENANTS AND ADDITIONAL AGREEMENTS
		

		
			5.1       Stock Ownership Governance.
		

		
			(a)        Lock-Up Period.   Excluding any transfers of Shares between Purchaser and any of its Affiliates, during the twelve (12) month period beginning on the date hereof and ending on the first anniversary thereof (the “Lock-Up Period”), Purchaser shall not, and shall not cause any other holder of the Shares to, without the prior written consent of the Company, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any Shares or enter into a transaction which would have the same effect.  The Purchaser acknowledges that the Company shall impose stop-transfer instructions with 
		

		
			
		

		
			

		 

		

			20

		

 

		

		
			respect to the Shares until the end of the Lock-Up Period in accordance with the transfer restrictions set forth in this Section 5.1(a).
		

		
			(b)        Market Stand-Off Agreement.   During the Lock-Up Period, Purchaser agrees that in connection with any registration of the Company’s securities that, upon the request of the Company or the underwriters managing any underwritten offering of the Company’s securities, Purchaser will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any Shares without the prior written consent of the Company or such underwriters, as the case may be, for such period of time within the Lock-Up Period from the effective date of such registration as the Company or the underwriters may specify.
		

		
			(c)        Remedies.   Without prejudice to the rights and remedies otherwise available to the parties, the Company shall be entitled to equitable relief by way of injunction if Purchaser or any other holder of the Shares breaches or threatens to breach any of the provisions of this Section 5.1.
		

		
			5.2       Non-Public Information.  Except as contemplated by the Collaboration Agreement, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information.  The Company understands and confirms that Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.
		

		
			5.3       Use of Proceeds.  The Company shall use the net proceeds from the sale of the Shares hereunder for working capital purposes and shall not use such proceeds: (a) for the redemption of any Common Stock or Common Stock Equivalents, or (b) in violation of FCPA or regulations of the Office of Foreign Assets Control of the U.S. Treasury Department.
		

		
			5.4       Public Disclosure.  The provisions of Sections 7.3 and 7.4 of the Collaboration Agreement shall be applicable, mutatis mutandis, with respect to any public disclosures regarding the proposed transactions contemplated by this Agreement or regarding the parties hereto or their affiliates.
		

		
			5.5       Listing of Common Stock, No Integrated Offerings. The Company shall take no action designed to, or which to the knowledge of the Company is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act.  The Company hereby agrees to use commercially reasonable efforts to maintain the listing of the Common Stock, including the Shares, on The NASDAQ Global Select Market.  The Company further agrees, if the Company applies to have the Common Stock traded on any other trading market, it will include in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed on such other trading market as promptly as possible.  The Company will take all action reasonably necessary to continue the listing and trading of its Common Stock, including the Shares, on The NASDAQ Global Select Market and will comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws or rules of The NASDAQ Global Select Market.  The Company has taken no action 
		

		
			
		

		
			

		 

		

			21

		

 

		

		
			designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from The NASDAQ Global Select Market nor has the Company received in the past twelve (12) months any notification that the Commission or FINRA is contemplating terminating such registration or listing. The Company currently meets the continuing eligibility requirements for listing on The NASDAQ Global Select Market.  The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company (except in the case of this clause (iii) as disclosed in the SEC Reports in connection with the private placement of shares of the Company’s Common Stock in April 2017). The Company agrees to file with the Commission in a timely manner all reports and other filings required of the Company under the Securities Act and the Exchange Act.  The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Shares in a manner that would require the registration under the Securities Act of the sale of the Shares to Purchaser or that would be integrated with the offer or sale of the Shares for purposes of the rules and regulations of The NASDAQ Global Select Market.
		

		
			5.6       Blue Sky Filings.  The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption, or to qualify the Shares, for sale to the Purchaser at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of the Purchaser.
		

		
			5.7       Legend Removal.
		

		
			(a)        Certificates evidencing the Shares shall not contain the legend set forth in Section 3.2(e) (i) following a sale of such Shares pursuant to a registration statement covering the resale of such Shares, while such registration statement is effective under the Securities Act; (ii) following any sale of such Shares pursuant to Rule 144; (iii) if such Shares are eligible for sale under Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions; or (iv) following the expiration of the Lock-Up Period; provided, however, that any transfer described in clause (i) or (ii) shall be in compliance with all applicable provisions of this Agreement, including, without limitation, Section 5.1(a) hereof.
		

		
			(b)        The Company agrees that at such time as any legend set forth in Section 3.2(e) is no longer required under this Section 5.7, the Company will, no later than three (3) Business Days following the delivery by the Purchaser to the Company or the Transfer Agent of a certificate representing Shares issued with such legend and receipt from the Purchaser by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, deliver or cause to be delivered to the Purchaser 
		

		
			
		

		
			

		 

		

			22

		

 

		

		
			a certificate representing such Shares that is free from such legend or, in the event that such shares are uncertificated, remove any such legend in the Company’s stock records.
		

		
			5.8       Participation in Future Financing.
		

		
			(a)        Subject to compliance with applicable securities laws, from the date hereof until the earlier of (i) the second anniversary of the Closing Date or (ii) expiration of the Term (as such term is defined in the Collaboration Agreement), upon (1) any issuance by the Company of unregistered shares of Common Stock or Common Stock Equivalents (a “Private Offering”) or (2) any issuance by the Company of registered shares of Common Stock or Common Stock Equivalents (a “Public Offering” and together with the Private Offering, a “Subsequent Financing”), in each case for cash consideration, indebtedness or a combination thereof, then for a Private Offering the Purchaser shall have the right to participate and with respect to a Public Offering the Purchaser shall have the right to participate by means of a side-by-side private placement including registration rights at least as favorable to the Purchaser as those set forth in Section 4.1 hereof, in an amount of the Subsequent Financing up to the Purchaser’s Pro-Rata Share (as defined below).  The Purchaser shall have the right to purchase the same securities as are offered in the Subsequent Financing and at the same price as the securities offered in the Subsequent Financing and on the same other terms (except for reasonable modifications in the terms of a Public Offering to adjust for a side-by-side private placement with registration rights at least as favorable to the Purchaser as those set forth in Section 4.1 hereof of any securities sold to the Purchaser) as such securities are offered to other investors in the Subsequent Financing.  For purposes of this Agreement, the Purchaser’s “Pro-Rata Share” shall be equal to the lesser of (x) the number of shares of Common Stock deemed to be beneficially owned by the Purchaser immediately prior to the closing of the Subsequent Financing (based upon documentation or written representation reasonably satisfactory to the Company), divided by the total number of shares of Common Stock outstanding (including any shares of Common Stock issuable upon conversion or exercise of outstanding Common Stock Equivalents deemed to be beneficially owned by the Purchaser and included in the numerator) immediately prior to the closing of the Subsequent Financing or (y) the number of shares of Common Stock that would result in Purchaser beneficially owning 15.0% of the outstanding shares of Common Stock of the Company immediately prior to the closing of the Subsequent Financing.
		

		
			(b)        At least five (5) Trading Days prior to the closing of a Public Offering or a Private Offering, as applicable, the Company shall deliver to the Purchaser a confidential notice of its intention to effect a Subsequent Financing (the “Subsequent Financing Notice”).  In the event of a Private Offering, the Subsequent Financing Notice shall be written and describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder and the name and contact information of the placement agent(s) for such Private Offering and shall include a copy of any term sheet or similar document (if any) that has been prepared for potential investors in such offering as an attachment.  In the event of a Public Offering, the Subsequent Financing Notice shall describe in reasonable detail the class of security being offered, the proposed amount of proceeds intended to be raised in such Public 
		

		
			
		

		
			

		 

		

			23

		

 

		

		
			Offering, and the estimated date and time at which the Company expects to enter into an underwriting agreement with the underwriters for the Public Offering (the “Pricing Time”).
		

		
			(c)        If the Purchaser desires to participate in a Private Offering or undertake a side-by-side private placement at the time of a Public Offering, then the Purchaser must provide a written notice to the Company by not later than 5:30 p.m. (New York City time) on the third (3rd) Trading Day after Purchaser has received a Subsequent Financing Notice and, in the case of a Public Offering, no later than the Pricing Time (provided that the Subsequent Financing Notice is delivered to the Purchaser at least two (2) Trading Days prior to the Pricing Time, in addition to in accordance with Section 5.8(b) hereof), stating the amount of the Purchaser’s elected participation.  If the Company receives no such notice from the Purchaser in the applicable time periods, the Purchaser shall be deemed to have notified the Company that it does not elect to participate in the Subsequent Financing or side-by-side private placement.  In the event that the Purchaser elects, or is deemed to have elected, not to purchase its full Pro Rata Share in the Subsequent Financing, the Purchaser will thereafter have no further right to participate in any future Subsequent Financing.
		

		
			(d)        Notwithstanding anything to the contrary in this Section 5.8 and unless otherwise agreed by the Purchaser, in the event the Company determines to abandon a Subsequent Financing, the Company shall, or shall cause the managing underwriter(s) or placement agent(s), as the case may be, to confirm such abandonment to the Purchaser in the same manner and on the same day as such abandonment is communicated to other potential investors.  If, by the twentieth (20th) day following delivery of the Subsequent Financing Notice, no public disclosure regarding a transaction with respect to the Subsequent Financing has been made, such Subsequent Financing shall be deemed to have been abandoned and the Purchaser shall be deemed to not be in possession of any material, non-public information with respect to the proposed Subsequent Financing by the Company, unless the Company advises the Purchaser that the Subsequent Financing has not been abandoned.  The Company understands and confirms that the Purchaser may rely on this Section 5.8(d) when effecting transactions in securities of the Company.
		

		
			(e)        Notwithstanding the foregoing, this Section 5.8 shall not apply in respect of an Exempt Issuance.
		

		
			(f)         Purchaser further agrees to execute such other documents and agreements as may reasonably be requested of Purchaser by the Company or placement agent(s), as the case may be, in connection with a Subsequent Financing.
		

		
			ARTICLE VI.
		

		
			 MISCELLANEOUS
		

		
			6.1       Termination.  This Agreement and the obligations of the parties hereunder may be terminated by the Company and the Purchaser, by providing mutual written consent to terminate.
		

		
			
		

		
			

		 

		

			24

		

 

		

		
			6.2       Fees and Expenses.  Each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.  The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Shares to Purchaser, and the Company shall pay all fees and expenses related to preparation and filing of any Registration Statement filed hereunder as contemplated by Article IV.
		

		
			6.3       Entire Agreement.  This Agreement, together with the exhibits and schedules hereto, contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into this Agreement.
		

		
			6.4       Notices.  Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth below at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth below on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.  The address for such notices and communications shall be as set forth below:
		

			
					
						If to the Company:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Syros Pharmaceuticals, Inc.

				
	
					
						 

					
					
						620 Memorial Drive, Suite 300

				
	
					
						 

					
					
						Cambridge, MA 02139

				
	
					
						 

					
					
						Attention:  Chief Legal Officer

				
	
					
						 

					
					
						Facsimile: (617) 744-1377

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						with a copy to:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						WilmerHale

				
	
					
						 

					
					
						60 State Street

				
	
					
						 

					
					
						Boston, Massachusetts 02109, USA

				
	
					
						 

					
					
						Attention: Steven D. Singer, Esq.

				
	
					
						 

					
					
						Facsimile: (617) 526-5000

				
	
					
						 

					
					
						 

				
	
					
						If to Purchaser:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Incyte Corporation

				
	
					
						 

					
					
						1801 Augustine Cut-Off

				
	
					
						 

					
					
						Wilmington, Delaware 19803, USA

				

		
			
		

		

		 

		

			25

		

 

	
					
						

					
						 

					
					
						Attention:  General Counsel

				
	
					
						 

					
					
						Facsimile: (302) 425-2707

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						with a copy to:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						King & Spalding LLP

				
	
					
						 

					
					
						101 Second Street, Suite 2300

				
	
					
						 

					
					
						San Francisco, California 94105, USA

				
	
					
						 

					
					
						Attention: Thomas E. Duley, Esq.

				
	
					
						 

					
					
						Facsimile: (415) 318-1300

				

		
			 
		

		
			6.5       Amendments; Waivers.  No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed by the Company and Purchaser.  No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
		

		
			6.6       Headings.  The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.
		

		
			6.7       Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.  The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Purchaser (other than by merger).  Purchaser may assign any or all of its rights under this Agreement to any Person to whom Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing to be bound, with respect to the transferred Shares, by the provisions of this Agreement that apply to “Purchaser.”
		

		
			6.8       No Third-Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.6.
		

		
			6.9       Governing Law.  This Agreement shall in all respects be governed by and construed in accordance with the laws of the State of Delaware, USA, including all matters of construction, validity and performance, in each case without reference to any conflict of law rules that might lead to the application of the laws of any other jurisdiction.
		

		
			6.10     Survival of Representation and Warranties.  The representations and warranties contained herein shall survive the Closing and the delivery of the Shares for the applicable statute of limitations.
		

		
			6.11     Execution in Counterparts.  This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to 
		

		
			
		

		
			

		 

		

			26

		

 

		

		
			each other party, it being understood that the parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.
		

		
			6.12     Severability.  If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.
		

		
			6.13     Replacement of Securities.  If any certificate or instrument evidencing any of the Shares is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.  The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Shares.
		

		
			6.14     Remedies.  In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, Purchaser and the Company will be entitled to specific performance under this Agreement.  The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in this Agreement and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.
		

		
			6.15     Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise this Agreement and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement or any amendments hereto. In addition, each and every reference to share prices and shares of Common Stock in this Agreement shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.
		

		
			6.16     WAIVER OF JURY TRIAL.  IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVE FOREVER TRIAL BY JURY.
		

		
			(Signature Pages Follow)
		

		
			
		

		
			

		 

		

			27

		

 

		

		
			IN WITNESS WHEREOF, the parties hereto have caused this Stock Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
		

			
					
						 

					
					
						 

				
	
					
						SYROS PHARMACEUTICALS, INC. 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						By: 

					
					
						/s/ Nancy Simonian

					
					
						 

				
	
					
						 

					
					
						Name:

					
					
						Nancy Simonian, M.D.

					
					
						 

				
	
					
						 

					
					
						Title:

					
					
						Chief Executive Officer

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						INCYTE CORPORATION

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Hervé Hoppenot

					
					
						 

				
	
					
						 

					
					
						Name:

					
					
						Hervé Hoppenot

					
					
						 

				
	
					
						 

					
					
						Title:

					
					
						President and Chief Executive Officer

					
					
						 

				

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			28

		

 

		

		
			AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT
		

		
			This Amendment No. 1 to Stock Purchase Agreement (this “Amendment”) is dated as of January 31, 2018 (the “Amendment Date”), between Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Incyte Corporation, a Delaware corporation (“Purchaser”), to amend that certain Stock Purchase Agreement, dated as of January 8, 2018, between the Company and Purchaser (the “Agreement”).  Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
		

		
			WHEREAS, in Section 5.8 of the Agreement, the Company granted to Purchaser the right to purchase up to Purchaser’s Pro-Rata Share in the event of a Subsequent Financing;
		

		
			WHEREAS, the Company intends to undertake a Public Offering, subject to market and other conditions (the “2018 Public Offering”); and
		

		
			WHEREAS, Purchaser, pursuant to the terms and conditions of the Agreement (as amended by this Amendment), desires to undertake a side-by-side private placement at the same time as the 2018 Public Offering, in an amount equal to Purchaser’s Pro-Rata Share and at a price per share equal to the public offering price per share that the Common Stock is sold to the public in the 2018 Public Offering (the “Public Offering Price”).
		

		
			NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained herein, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and Purchaser agree as follows:
		

		
			1.         Amendment of Section 2.1.  Section 2.1 of the Agreement is hereby deleted in its entirety and the following is inserted in lieu thereof:
		

		
			“Subject to the terms and conditions of this Agreement, the Company agrees to sell to Purchaser at the Initial Closing, free and clear of all Liens, and Purchaser agrees to purchase from the Company at the Initial Closing, 793,021 shares of Common Stock (the “Initial Shares”) at a price per share of $12.61 for an aggregate purchase price of $9,999,994.81 (the “Initial Purchase Price”).  Subject to the satisfaction or waiver of the conditions set forth in Section 2.4, the Initial Closing shall take place remotely via the exchange of documents and signatures at 10:00 a.m. Eastern Time on January 8, 2018, or at such other time and location as the Company and Purchaser shall mutually agree (which time and location are designated as the “Initial Closing” and the date thereof as the “Initial Closing Date”).  Subject to the terms and conditions of this Agreement, the Company agrees to sell to Purchaser at the Additional Closing, free and clear of all Liens, and Purchaser agrees to purchase from the Company at the Additional Closing, 121,995 shares of Common Stock (“Additional Shares”) at a price per share of $9.55 for an aggregate purchase price of $1,165,052.25 (the “Additional Purchase Price”).  Upon satisfaction or waiver of the conditions set forth in Section 2.4, the Additional Closing shall take place remotely via the exchange of documents and signatures concurrently with the closing of the 2018 Public Offering, which the Company and Purchaser anticipate will be on or about two (2) Business Days following the Amendment Date, or at such other time and location as the Company and Purchaser shall mutually agree (which time 
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			and location are designated as the “Additional Closing” and the date thereof as the “Additional Closing Date”).  The shares of Common Stock issued to Purchaser pursuant to this Agreement (including the Initial Shares and any Additional Shares) shall be referred to in this Agreement as the “Shares,” unless otherwise specified.  Similarly, in the event there is more than one closing, the term “Closing” shall apply to each such closing, as applicable; the term “Closing Date” shall apply to the date of each such closing, as applicable; and the term “Purchase Price” shall apply to the Initial Purchase Price or the Additional Purchase Price, as applicable, in each case, unless otherwise specified.”
		

		
			2.         Amendment of Section 2.4.  Section 2.4 of the Agreement is hereby amended by:
		

		
			(a)        Deleting the phrase “the date hereof” where it appears therein and inserting in lieu thereof “the date hereof, as of the Amendment Date and as of each Closing Date.”
		

		
			(b)        Inserting the following as new Section 2.4(a)(v) and new Section 2.4(b)(x):
		

		
			“Solely with respect to the Additional Closing, any of J.P. Morgan Securities LLC, Cowen and Company, LLC or Piper Jaffray & Co., the representatives of the several underwriters for the 2018 Public Offering (the “Underwriters”), shall have purchased, concurrent with the purchase of the Additional Shares by Purchaser hereunder, the Underwritten Shares (as defined in the Underwriting Agreement to effect the 2018 Public Offering (the “Underwriting Agreement”)) at the Public Offering Price (less any underwriting discounts or commissions).”
		

		
			3.         Amendment of Sections 3.1 and 3.2.  The first sentence of each of Sections 3.1 and 3.2 of the Agreement is hereby amended by deleting the phrase “the date hereof” where it appears therein and inserting in lieu thereof “the date hereof and as of the Amendment Date.”
		

		
			4.         Amendment of Section 3.1(a).  The second sentence of Section 3.1(a) of the Agreement is hereby deleted in its entirety and the following is inserted in lieu thereof:
		

		
			“The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to this Agreement and the 2018 Public Offering, pursuant to the exercise of stock options under the Company’s stock incentive plans and the issuance of shares of Common Stock pursuant to the Company’s at-the-market sales agreement.”
		

		
			5.         Amendment of Section 5.1.  Section 5.1 of the Agreement is hereby deleted in its entirety and the following is inserted in lieu thereof:
		

		
			“5.1      Stock Ownership Governance.
		

		
			(a)        Lock-Up Period.   Excluding any transfers of Initial Shares between Purchaser and any of its Affiliates, during the twelve (12) month period beginning on the Initial Closing Date and ending on the first anniversary thereof (the “Lock-Up Period”), Purchaser shall not, and shall not cause any other holder of the Initial Shares to, without the prior written consent of the Company, sell, contract to sell, pledge or otherwise 
		

		
			
		

		
			

		 

		

			2

		

 

		

		
			dispose of, directly or indirectly, any Initial Shares or enter into a transaction which would have the same effect.  The Purchaser acknowledges that the Company shall impose stop-transfer instructions with respect to the Initial Shares until the end of the Lock-Up Period in accordance with the transfer restrictions set forth in this Section 5.1(a).
		

		
			(b)        Market Stand-Off Agreement.   During the Lock-Up Period, Purchaser agrees that in connection with any registration of the Company’s securities that, upon the request of the Company or the underwriters managing any underwritten offering of the Company’s securities, Purchaser will not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any Initial Shares without the prior written consent of the Company or such underwriters, as the case may be, for such period of time within the Lock-Up Period from the effective date of such registration as the Company or the underwriters may specify.
		

		
			(c)        Remedies.  Without prejudice to the rights and remedies otherwise available to the parties, the Company shall be entitled to equitable relief by way of injunction if Purchaser or any other holder of the Initial Shares breaches or threatens to breach any of the provisions of this Section 5.1.”
		

		
			6.         Amendment of Section 5.7(a).  Clause (iv) of Section 5.7(a) of the Agreement is hereby deleted in its entirety and the following is inserted in lieu thereof: “(iv) following the expiration of the Lock-Up Period (solely as to the Initial Shares);”.
		

		
			7.         Amendment of Section 5.8(a).  The first sentence of Section 5.8(a) of the Agreement is hereby amended by deleting the phrase “Closing Date” where it appears therein and inserting in lieu thereof “Initial Closing Date.”
		

		
			8.         Underwriters Exercise of Overallotment.
		

		
			8.1       Purchase and Sale of Option Shares; Option Closings.  In the event that the Underwriters exercise, in full or in part, their right under the Underwriting Agreement to purchase additional shares of Common Stock to cover overallotments, if any, the Company shall provide written notice to Purchaser of such exercise in accordance with Section 5.8 of the Agreement (as amended by this Amendment).  In the event that Purchaser elects, pursuant to Section 5.8 of the Agreement (as amended by this Amendment), to purchase its Pro-Rata Share of shares of Common Stock in relation to any such exercise (“Option Shares”), subject to the terms and conditions of the Agreement (as amended by this Amendment), the Company shall sell to Purchaser at an Option Closing (as defined below), free and clear of all Liens, and Purchaser agrees to purchase from the Company at such Option Closing, the applicable Option Shares at a price per share of $9.55 for an aggregate purchase price equal to the price per share multiplied by the number of Option Shares purchased in such Option Closing (for each Option Closing, if any, the “Option Purchase Price”).  Upon satisfaction or waiver of the conditions set forth in Section 2.4 of the Agreement (as amended by this Amendment), any Option Closing shall take place remotely via the exchange of documents and signatures concurrently with the closing of the Underwriters’ purchase of shares of Common Stock upon exercise of their overallotment option, or at such other time and location as the Company and Purchaser shall mutually agree (each such 
		

		
			
		

		
			

		 

		

			3

		

 

		

		
			time and location are designated as an “Option Closing” and the date thereof as an “Option Closing Date”).
		

		
			8.2.      Amendment of Section 2.1 for an Option Closing.  In the event of an Option Closing, the last two sentences of Section 2.1 of the Agreement (as amended herein) shall be deleted in their entirety and the following inserted in lieu thereof:
		

		
			“The shares of Common Stock issued to Purchaser pursuant to this Agreement (including the Initial Shares, the Additional Shares and any Option Shares) shall be referred to in this Agreement as the “Shares,” unless otherwise specified.  Similarly, in the event there is more than one closing, the term “Closing” shall apply to each such closing, as applicable; the term “Closing Date” shall apply to the date of each such closing, as applicable; and the term “Purchase Price” shall apply to the Initial Purchase Price, the Additional Purchase Price or an Option Purchase Price, as applicable, in each case, unless otherwise specified.”
		

		
			8.3.      Amendment of Section 2.4 for an Option Closing.  In the event of an Option Closing, Section 2.4 of the Agreement shall be amended by inserting the following as new Section 2.4(a)(vi) and new Section 2.4(b)(xi):
		

		
			“Solely with respect to an Option Closing, the Underwriters shall have purchased, concurrent with the purchase of the Option Shares by Purchaser hereunder, the Option Shares (for purposes of this clause, as defined in the Underwriting Agreement) at the Public Offering Price (less any underwriting discounts or commissions).”
		

		
			9.         Termination of Amendment.  This Amendment and the obligations, representations and warranties of the parties under the Agreement (as amended by this Amendment) with respect to the purchase of Additional Shares shall automatically terminate and be of no further force and effect upon the earliest to occur, if any, of: (a) either the Company, on the one hand, or the Underwriters, on the other hand, advising the other in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the 2018 Public Offering, (b) termination of the Underwriting Agreement (other than the provisions thereof which survive termination) prior to the sale of any of the Common Stock to the Underwriters, or (c) the Underwriting Agreement has not become effective by March 31, 2018.
		

		
			10.       Entire Agreement.  The Agreement, as supplemented and modified by this Amendment, together with the exhibits and schedules thereto, contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into the Agreement.
		

		
			11.       Governing Law.  This Amendment shall in all respects be governed by and construed in accordance with the laws of the State of Delaware, USA, including all matters of construction, validity and performance, in each case without reference to any conflict of law rules that might lead to the application of the laws of any other jurisdiction.
		

		
			
		

		
			

		 

		

			4

		

 

		

		
			12.       Execution in Counterparts.  This Amendment may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart.  In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.
		

		
			13.       Remaining Provisions of the Agreement.  Except as provided herein, each of the other provisions of the Agreement shall remain in full force and effect.
		

		
			14.       References.  Upon the effectiveness of this Amendment, on and after the date hereof, each reference in the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Agreement, as amended hereby.
		

		
			(Signature Pages Follow)
		

		
			 
		

		
			 
		

		
			

		 

		

			5

		

 

		

		
			IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to Stock Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
		

			
					
						 

					
					
						 

				
	
					
						SYROS PHARMACEUTICALS, INC.

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Nancy Simonian

					
					
						 

				
	
					
						 

					
					
						Name:

					
					
						Nancy Simonian, M.D.

					
					
						 

				
	
					
						 

					
					
						Title:

					
					
						Chief Executive Officer

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						INCYTE CORPORATION

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Hervé Hoppenot

					
					
						 

				
	
					
						 

					
					
						Name:

					
					
						Hervé Hoppenot

					
					
						 

				
	
					
						 

					
					
						Title:

					
					
						President and Chief Executive Officer

					
					
						 

				

		
			 
		

		 

		

			[Signature Page to Amendment No. 1 to Stock Purchase Agreement]Exh_10_13

		
			Exhibit 10.13
		

			
					
						 

					
					
						 

					
						 

					
						 

				
	
					
						

					
					
						620 Memorial Drive, Suite 300

					
						Cambridge, Ma 02139

					
						Syros.com

				

		
			 
		

		
			November 6, 2017
		

		
			Jeremy Springhorn
		

		
			Via e-mail
		

		
			Dear Jeremy:
		

		
			On behalf of Syros Pharmaceuticals, Inc. (the "Company"), I am pleased to extend the following offer and set forth the terms of your employment with the Company:
		

		
			1.          You will be employed to serve on a full-time basis as Chief Business Officer effective November 13,  2017.  As Chief Business Officer, you will report to Nancy Simonian, the Company’s President and Chief Executive Officer, and be responsible for leading all aspects of the Company’s business development initiatives, playing a key role in the Company’s strategic planning process, and such other duties as may from time to time be reasonably assigned to you by the Company.
		

		
			2.          Your salary will be $390,000 per year, paid semi-monthly in arrears in accordance with the Company's normal payroll processes and subject to tax and other withholdings as required by law. Such salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of the Company. You will receive performance reviews in accordance with the Company’s standard practice for executive officers.
		

		
			3.          You may participate in any and all bonus and benefit programs that the Company establishes and makes available to its employees from time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs.  Specifically, you will be eligible to receive a bonus of up to 40% of your base salary in your first full year of employment with the Company, as approved by the Board of Directors.  Future bonus eligibility will be approved by the Board of Directors.  Any bonus made pursuant to this paragraph will be paid no later than March 15th of the year immediately following the year to which the applicable annual bonus relates.
		

		
			4.         Without otherwise limiting the "at-will" nature of your employment, in the event your employment is terminated by the Company without Cause or by you for Good Reason (each as defined below), you shall be entitled to the base salary that has accrued and to which you are entitled as of the effective date of such termination, and further, subject to the conditions set forth in the second paragraph of this Section 4, the Company shall, for a period of nine (9) months following your termination date: (i) continue to pay you, in accordance with the Company's regularly established payroll procedure, your base salary as severance; and (ii) provided you are eligible for and timely elect to continue receiving group medical insurance pursuant to the "COBRA" law, continue to pay the share of the premium for health dental and vision coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage, unless the Company's provision of such COBRA payments will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply. If, within the three months prior to a Change in Control or in the twelve months following a Change in Control, the Company, or its successor, terminates your employment without Cause or you resign for Good Reason, the Company, subject to the conditions set forth in the second paragraph of this Section 4, will: (a) extend the severance benefits described in (i) and (ii) above for an additional three months, such that the total severance benefit period shall be one (1) year; (b) pay you a lump sum amount equal to your target bonus in effect for the fiscal year in which your separation from employment occurs; and (c) accelerate the 
		

		
			
		

		
			

		 

 

		

		
			vesting of all unvested stock options held by you as of the date your employment is terminated such that 100% of such options shall become fully vested and exercisable effective as of such date.
		

		
			Notwithstanding the foregoing, you will not be entitled to receive any severance benefits unless, within sixty (60) days following the date of termination, you  have executed a severance and release of claims agreement in a form prescribed by the Company or persons affiliated with the Company (which will include, without limitation, a release of all releasable claims and non-disparagement and cooperation obligations with Company paying reasonable expenses incurred by you in connection with such cooperation, but not including restrictive covenants with respect to non-competition or non-solicitation greater than those contained in the Ancillary Agreements).  For clarity, the foregoing release will not affect your rights to indemnification or defense, vested benefits under benefit or equity plans, or under ERISA or COBRA.  Any severance payments shall be paid, or commence on the first payroll period following the date the release becomes effective (the "Payment Date").  Notwithstanding the foregoing, if the 60th day following the date of termination occurs in the calendar year following the calendar year of the termination, then the Payment Date shall be no earlier than January 1st of such subsequent calendar year.   If you die after you execute the release of claims and before you receive the severance payments you are entitled to, the remaining payments will be paid to your spouse.  If she is not alive at the time, the payments will be made to your estate.
		

		
			For purposes of this Agreement, "Change in Control" means any transaction or series of related transactions (a) the result of which is a change in the ownership of the Company, such that more than 50% of the equity securities of the Company are acquired by any person or group (as such terms are defined for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended) that does not own capital stock of the Company of the effective date of such change in control, (b) that results in the sale of all or substantially all of the assets of the Company, or (c) that results in the consolidation or merger of  the Company with or into another corporation or corporations or other entity in which the Company is not the survivor (except any such corporation or entity controlled, directly or indirectly, by the Company).
		

		
			"Cause" means: (a) your conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (b) you have (i) engaged in material dishonesty, willful misconduct or gross negligence, (ii) breached or threatened to breach either or both of the Ancillary Agreements (as defined below), (iii) materially violated a Company policy or procedure causing or threatening to cause substantial injury to the Company, and/or (iv) willfully refused to perform your assigned duties to the Company, following written notice of such refusal or breach by the Company and a period of thirty (30) days to cure the same.
		

		
			"Good Reason" means the occurrence of one or more of the following without your written consent: (a) a material reduction in your authority, duties and/or responsibilities as compared to your authority, duties and/or responsibilities in effect immediately prior to the occurrence of the event (for example, but not by way of limitation, this determination will include an analysis of whether you maintain at least the same level, scope and type of duties and responsibilities with respect to the management, strategy, operations and business of the Company), or (b) a material reduction in your base compensation as compared to your base compensation in effect immediately prior to the occurrence of the event; provided, however, that no such occurrence shall constitute Good Reason unless: (i) you give the Company a written notice of termination for Good Reason not more than ninety (90) days after the initial existence of the condition, (ii) the grounds for termination (if susceptible to correction) are not corrected by the Company within thirty (30) days of its receipt of such notice, and (iii) your termination of employment occurs within one (1) year following the Company's receipt of such notice.
		

		
			5.          Subject to the approval of the Board of Directors of the Company (the “Board”), the Company will grant to you an option (a "Time-Based Option") under the Company's 2016 Stock Incentive Plan (the "Plan") for the purchase of 150,000 shares of common stock of the Company 
		

		
			
		

		
			

		 

 

		

		
			(“Common Stock”), at a price per share equal to the closing price of the Common Stock on the date of Board approval, which option shall be granted within 30 days of your first day of employment. The Time-Based Option shall vest (i) as to 25% of the shares underlying the option on the one-year anniversary of your first day of employment, and (ii) as to the remaining shares underlying the option in equal monthly installments for the next 36 months thereafter, becoming fully vested on the fourth anniversary of your first day of employment, provided that you remain employed by us on the applicable vesting date. Subject to the approval of the Board, you shall also be granted an option (a "Performance-Based Option") under the Plan to purchase an additional 50,000 shares of Common Stock of the Company, at a price per share equal to the closing price of the Common Stock on the date of Board approval, which option shall be granted within 30 days of your first day of employment and vest six years from your first day of employment, subject to accelerated vesting according to the following schedule: (i) 33% upon the earlier of (A) achievement of clinical proof of concept with a molecule beyond SY-1425 or (B) the start of the first pivotal trial; and (ii) 67% upon signing by the Company of a business development, collaboration or partnership agreement around the Company’s platform or one of its product candidates other than  the transaction previously disclosed to you, in each cased based on parameters approved by the Board, and provided that the Participant remains employed by the Company on the applicable vesting date.
		

		
			Each of the Time-Based Option and the Performance-Based Option shall be subject to all terms herein,  including the acceleration of vesting under the circumstances set forth in paragraph 4 above, and other provisions set forth in the Plan and in a separate option agreement.
		

		
			You will be eligible to receive such future long-term incentive awards as the Board shall deem appropriate.
		

		
			6.          You will be required to execute an Invention and Non-Disclosure Agreement and a Non-Competition and Non-Solicitation Agreement in the forms attached as Exhibit A and Exhibit B, respectively, as a condition of employment (such agreements are referred to as "Ancillary Agreements").  Upon your appointment by the Board of Directors as an “executive officer” of the Company, the Company will enter into an Indemnification Agreement with you in the form currently approved by the Board of Directors.
		

		
			7.          You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.
		

		
			8.          You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work in the United States.  If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company.
		

		
			9.          This letter shall not be construed as an agreement, either expressed or implied, to employ you for any stated term, and shall in no way alter the Company's policy of employment at will, under which both you and the Company remain free to terminate the employment relationship, with or without cause, at any time, with or without notice.   Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.
		

		
			10.        This letter is intended to provide payments that are exempt from or compliant with Section 409A (as defined in Attachment A), and should be interpreted consistent with that intent.
		

		
			THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK
		

		
			
		

		
			

		 

 

		

		
			If you agree with the employment provisions of this letter, please sign the letter and exhibits, scan the signature pages and email to Lisa Roberts at lroberts@syros.com.  If you do not accept this offer by November 8, 2017, this offer will be revoked.
		

			
					
						Very truly yours,

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						/s/ Nancy Simonian

					
					
						 

				
	
					
						Name:

					
					
						Nancy Simonian

					
					
						 

				
	
					
						Title:

					
					
						President & Chief Executive Officer

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						The foregoing correctly sets forth the terms of my

					
					
						 

				
	
					
						employment by Syros Pharmaceuticals, Inc.

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						/s/ Jeremy Springhorn

					
					
						Date:

					
					
						 11/9/17

				
	
					
						Jeremy Springhorn

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

 

		

		
			Attachment A
		

		
			Payments Subject to Section 409A
		

		
			1.          Subject to this Attachment A, any severance payments that may be due under the letter agreement shall begin only upon the date of your "separation from service" (determined as set forth below) which occurs on or after the termination of your employment. The following rules shall apply with respect to distribution of the severance payments, if any, to be provided to you under the letter agreement, as applicable:
		

		
			(a)        It is intended that each installment of the severance payments under the letter agreement provided under shall be treated as a separate “payment" for purposes of Section 409A of the Internal Revenue Code of 1986, as amended ("Section 409A"). Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments except to the extent specifically permitted or required by Section 409A.
		

		
			(b)        If, as of the date of your "separation from service" from the Company, you are not a "specified employee" (within the meaning of Section 409A), then each installment of the severance payments shall be made on the dates and terms set forth in the letter agreement.
		

		
			(c)        If, as of the date of your "separation from service" from the Company, you are a "specified employee" (within the meaning of Section 409A), then:
		

		
			(i)         Each installment of the severance payments due under the letter agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when your separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section l.409A-l (b)(4) to the maximum extent permissible under Section 409A and shall be paid on the dates and terms set forth in the letter agreement; and
		

		
			(ii)        Each installment of the severance payments due under the letter agreement that is not described in this Attachment A, Section 1(c)(i) and that would, absent this subsection, be paid within the six-month period following your "separation from service" from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six­ month period and paid in a lump sum on the date that is six months and one day following your separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A- 1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of your second taxable year following the taxable year in which the separation from service occurs.
		

		
			2.          The determination of whether and when your separation from service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section l.409A-l (h). Solely for purposes of this Attachment A, Section 2, "Company" shall include all persons with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Internal Revenue Code of 1986, as amended.
		

		
			
		

		
			

		 

 

		

		
			3.          The Company makes no representation or warranty and shall have no liability to you or to any other person if any of the provisions of the letter agreement (including this Attachment) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.
		

		
			
		

		
			

		 

 

		

		
			Exhibit A
		

		
			INVENTION AND NON-DISCLOSURE AGREEMENT
		

		
			This Agreement is made by and between Syros Pharmaceuticals, Inc., a Delaware corporation (hereinafter referred to collectively with its subsidiaries as the “Company”), and Jeremy Springhorn (the “Employee”).
		

		
			In consideration of the employment or the continued employment of the Employee by the Company, the Company and the Employee agree as follows:
		

		
			Condition of Employment.
		

		
			The Employee acknowledges that his/her employment and/or the continuance of that employment with the Company is contingent upon his/her agreement to sign and adhere to the provisions of this Agreement. The Employee further acknowledges that the nature of the Company's business is such that protection of its proprietary and confidential information is critical to the business' survival and success.
		

		
			Proprietary and Confidential Information.
		

		
			The Employee agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning the Company’s business or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company.  By way of illustration, but not limitation, Proprietary Information may include discoveries, inventions, products, product improvements, product enhancements, processes, methods, techniques, formulas, compositions, compounds, negotiation strategies and positions, projects, developments, plans (including business and marketing plans), research data, clinical data, financial data (including sales costs, profits, pricing methods), personnel data, computer programs (including software used pursuant to a license agreement), customer, prospect and supplier lists, and contacts at or knowledge of customers or prospective customers of the Company.  The Employee will not disclose any Proprietary Information to any person or entity other than employees of the Company or use the same for any purposes (other than in the performance of his/her duties as an employee of the Company) without written approval by an officer of the Company, either during or after his/her employment with the Company, unless and until such Proprietary Information has become public knowledge without fault by the Employee.  While employed by the Company, the Employee will use the Employee's best efforts to prevent unauthorized publication or disclosure of any of the Company’s Proprietary Information.
		

		
			The Employee agrees that all files, documents, letters, memoranda, reports, records, data, sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible or intangible material containing Proprietary Information, whether created by the Employee or others, which shall come into his/her custody or possession, shall be and are the exclusive property of the Company to be used by the Employee only in the performance of his/her duties for the Company and shall not be copied or removed from the Company premises except in the pursuit of the business of the Company.  All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Employee shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) termination of his/her
		

		
			
		

		
			

		 

 

		

		
			employment.  After such delivery, the Employee shall not retain any such materials or copies thereof or any such tangible property.
		

		
			The Employee agrees that his/her obligation not to disclose or to use information and materials of the types set forth in paragraphs 2(a) and 2(b) above, and his/her obligation to return materials and tangible property, set forth in paragraph 2(b) above, also extends to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Employee in the course of the Company’s business.
		

		
			Notwithstanding the provisions of (a)-(c) above, nothing in this Agreement prohibits the Employee from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information to government agencies or participating in government agency investigations or proceedings.  The Employee is not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of information the Employee obtained through a communication that was subject to the attorney-client privilege.  Further, notwithstanding the Employee’s confidentiality and nondisclosure obligations, the Employee is hereby advised as follows pursuant to the Defend Trade Secrets Act: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.”
		

		
			Developments.
		

		
			The Employee will make full and prompt disclosure to the Company of all discoveries, inventions, improvements, enhancements, processes, methods, techniques, developments, software, and works of authorship, whether patentable or not, which are created, made, conceived or reduced to practice by him/her or under his/her direction or jointly with others during his/her employment by the Company, whether or not during normal working hours or on the premises of the Company (all of which are collectively referred to in this Agreement as “Developments”).
		

		
			The Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all his/her right, title and interest in and to all Developments and all related patents, patent applications, copyrights and copyright applications.  However, this paragraph 3(b) shall not apply to Developments which do not relate to the business or research and development conducted or planned to be conducted by the Company at the time such Development is created, made, conceived or reduced to practice and which are made and conceived by the Employee not during normal working hours, not on the Company’s premises and not using the Company’s tools, devices, equipment or Proprietary Information.  The Employee understands that, to the extent this Agreement shall be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph 3(b) shall be interpreted not to
		

		
			
		

		
			

		 

 

		

		
			apply to any invention which a court rules and/or the Company agrees falls within such classes.  The Employee also hereby waives all claims to moral rights in any Developments.
		

		
			The Employee agrees to cooperate fully with the Company, both during and after his/her employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Developments.  The Employee shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Development.  The Employee further agrees that if the Company is unable, after reasonable effort, to secure the signature of the Employee on any such papers, any executive officer of the Company shall be entitled to execute any such papers as the agent and the attorney-in-fact of the Employee, and the Employee hereby irrevocably designates and appoints each executive officer of the Company as his/her agent and attorney-in-fact to execute any such papers on his/her behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Development, under the conditions described in this sentence.
		

		
			Other Agreements.
		

		
			The Employee represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with the Company, to refrain from competing, directly or indirectly, with the business of such previous employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party.  The Employee further represents that his/her performance of all the terms of this Agreement and the performance of his/her duties as an employee of the Company do not and will not conflict with or breach any agreement with any prior employer or other party to which the Employee is a party (including without limitation any nondisclosure or non-competition agreement), and that the Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.
		

		
			United States Government Obligations.
		

		
			The Employee acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work.  The Employee agrees to be bound by all such obligations and restrictions which are made known to the Employee and to take all action necessary to discharge the obligations of the Company under such agreements.
		

		
			Miscellaneous.
		

		
			Equitable Remedies.  The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose.  The Employee agrees that any breach of this Agreement is likely to cause the Company substantial and irrevocable damage which is difficult to measure.  Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall have
		

		
			
		

		
			

		 

 

		

		
			the right to obtain an injunction from a court restraining such a breach or threatened breach and the right to specific performance of the provisions of this Agreement and the Employee hereby waives the adequacy of a remedy at law as a defense to such relief.
		

		
			Obligations to Third Parties.  The Employee acknowledges and represents that this agreement and the Employee’s employment with the Company will not violate any continuing obligation the Employee has to any former employer or other third party.
		

		
			Disclosure of this Agreement.  The Employee hereby authorizes the Company to notify others, including but not limited to customers of the Company and any of the Employee’s future employers or prospective business associates, of the terms and existence of this Agreement and the Employee’s continuing obligations to the Company hereunder.
		

		
			Not Employment Contract.  The Employee acknowledges that this Agreement does not constitute a contract of employment, does not imply that the Company will continue his/her employment for any period of time and does not change the at-will nature of his/her employment.
		

		
			Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business, provided, however, that the obligations of the Employee are personal and shall not be assigned by him or her.  The Employee expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.
		

		
			Severability.  In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.
		

		
			Waivers.  No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.  A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.
		

		
			Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflicts of laws provisions thereof).  Any action, suit, or other legal proceeding which is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.  The Company and the Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement.
		

		
			Entire Agreement; Amendment.  This Agreement supersedes all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement.  This Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Employee and the Company.  The Employee
		

		
			
		

		
			

		 

 

		

		
			agrees that any change or changes in his/her duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.
		

		
			Captions.  The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.
		

		
			THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.
		

		
			WITNESS our hands and seals:
		

			
					
						 

					
					
						SYROS PHARMACEUTICALS, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						Date:

					
					
						 

					
					
						 

					
					
						By:

					
					
						/s/ Nancy Simonian

				
	
					
						 

					
					
						Name:

					
					
						Nancy Simonian

				
	
					
						 

					
					
						Title:

					
					
						Chief Executive Officer

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						Date:

					
					
						11/9/17

					
					
						  /s/ Jeremy Springhorn

				
	
					
						 

					
					
						 

					
					
						       Jeremy Springhorn

				

		
			 
		

		
			
		

		
			

		 

 

		

		
			Exhibit B
		

		
			NON-COMPETITION AND NON-SOLICITATION AGREEMENT
		

		
			This Agreement is made between Syros Pharmaceuticals, Inc., a Delaware corporation (hereinafter referred to collectively with its subsidiaries as the “Company”), and Jeremy Springhorn (the “Employee”).
		

		
			For good consideration and in consideration of the employment or continued employment of the Employee by the Company, including the equity consideration in the Company, the Employee and the Company agree as follows:
		

		
			1.         Non-Competition and Non-Solicitation.  While the Employee is employed by the Company and for a period of one year after the termination or cessation of such employment for any reason, the Employee will not directly or indirectly:
		

		
			(a)        Engage or assist others in engaging in any business or enterprise (whether as owner, partner, officer, director, employee, consultant, investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company) that is competitive with the Company’s business, including but not limited to any business or enterprise that develops, manufactures, markets, licenses, sells or provides any product or service that competes with any product or service developed, manufactured, marketed, licensed, sold or provided, or planned to be developed, manufactured, marketed, licensed, sold or provided, by the Company while the Employee was employed by the Company; or
		

		
			Notwithstanding the foregoing, Section 1(a) shall not preclude the Employee from becoming an employee of, or from otherwise providing services to, a separate division or operating unit of a multi-divisional business or enterprise (a “Division”) if: (i) the Division by which the Employee is employed, or to which the Employee provides services, is not competitive with the Company’s business (within the meaning of Section 1(a)), (ii) the Employee does not provide services, directly or indirectly, to any other division or operating unit of such multi-divisional business or enterprise which is competitive with the Company’s business (within the meaning of Section 1(a)) (individually, a “Competitive Division” and collectively, the “Competitive Divisions”) and (iii) the Competitive Divisions, in the aggregate, accounted for less than one-third of the multi-divisional business or enterprises’ consolidated revenues for the fiscal year, and each subsequent quarterly period, prior to the Employee’s commencement of employment with the Division.
		

		
			(b)        Either alone or in association with others, solicit, divert or take away, or attempt to divert or take away, the business or patronage of any of the clients, customers, or business partners of the Company which were contacted, solicited, or served by the Company during the 12-month period prior to the termination or cessation of the Employee’s employment with the Company; or
		

		
			(c)        Either alone or in association with others (i) solicit or (ii) hire, or recruit or attempt to hire, or engage or attempt to engage as an independent contractor, any person who was employed or otherwise engaged by the Company at any time during the term of the Employee’s employment with the Company; provided, that this clause (ii) shall not apply to the recruitment or hiring or other engagement of any individual whose employment or other
		

		
			
		

		
			

		 

 

		

		
			engagement with the Company was terminated by the Company or the individual has resigned from the Company   for a period of six months or longer.
		

		
			(d)        Extension.  If the Employee violates the provisions of any of the preceding paragraphs of this Section 1, the Employee shall continue to be bound by the restrictions set forth in such paragraph until a period of one year has expired without any violation of such provisions.
		

		
			2.         Miscellaneous.
		

		
			(a)        Equitable Remedies.  The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose.  The Employee agrees that any breach of this Agreement is likely to cause the Company substantial and irrevocable damage which is difficult to measure.  Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall have the right to obtain an injunction from a court restraining such a breach or threatened breach and the right to specific performance of the provisions of this Agreement and the Employee hereby waives the adequacy of a remedy at law as a defense to such relief.
		

		
			(b)        Obligations to Third Parties.  The Employee acknowledges and represents that this agreement and the Employee’s employment with the Company will not violate any continuing obligation the Employee has to any former employer or other third party.
		

		
			(c)        Disclosure of this Agreement.  The Employee hereby authorizes the Company to notify others, including but not limited to customers of the Company and any of the Employee’s future employers or prospective business associates, of the terms and existence of this Agreement and the Employee’s continuing obligations to the Company hereunder.
		

		
			(d)        Not Employment Contract.  The Employee acknowledges that this Agreement does not constitute a contract of employment, does not imply that the Company will continue his/her employment for any period of time and does not change the at-will nature of his/her employment.
		

		
			(e)        Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business, provided, however, that the obligations of the Employee are personal and shall not be assigned by him or her.  The Employee expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.  Notwithstanding the foregoing, if the Company is merged with or into a third party which is engaged in multiple lines of business, or if a third party engaged in multiple lines of business succeeds to the Company’s assets or business, then for purposes of Section 1(a), the term “Company” shall mean and refer to the business of the Company as it existed immediately prior to such event and as it subsequently develops and not to the third party’s other businesses.
		

		
			(f)        Interpretation.  If any restriction set forth in Section 1 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be
		

		
			
		

		
			

		 

 

		

		
			interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.
		

		
			(g)        Severability.  In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.
		

		
			(h)        Waivers.  No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.  A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.
		

		
			(i)         Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflicts of laws provisions thereof).  Any action, suit, or other legal proceeding which is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.  The Company and the Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement.
		

		
			(j)         Entire Agreement; Amendment.  This Agreement supersedes all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement.  This Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Employee and the Company.  The Employee agrees that any change or changes in his/her duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.
		

		
			(k)        Captions.  The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.
		

		
			[Remainder of this page intentionally left blank.]
		

		
			 
		

		
			
		

		
			

		 

 

		

		
			THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.
		

			
					
						 

					
					
						 

					
					
						SYROS PHARMACEUTICALS, INC.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Date:

					
					
						 

					
					
						 

					
					
						By:

					
					
						/s/ Nancy Simonian

				
	
					
						 

					
					
						 

					
					
						Name:

					
					
						Nancy Simonian

				
	
					
						 

					
					
						 

					
					
						Title:

					
					
						Chief Executive Officer

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Date:

					
					
						11/9/17

					
					
						 

					
					
						/s/ Jeremy Springhorn

				
	
					
						 

					
					
						 

					
					
						Jeremy Springhorn

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]